First patient with marginal zone lymphoma to receive purified CAR-T cells in trial at MUSC Hollings Cancer Center, in partnership with Hess and Mehrotra, recovering at home.

The first patient to receive purified CAR-T cells manufactured at MUSC Hollings Cancer Center is recovering at home after participating in a clinical trial. The treatment, carried out in partnership by Brian Hess, M.D., and Shikhar Mehrotra, Ph.D., is hoped to have fewer side effects and longer-lasting results than commercial CAR-T cells on the market. The patient, Ted Kopacko, who has lived with marginal zone lymphoma for 11 years, hopes this treatment will alleviate his dependence on maintenance drugs.

February 05, 2024
5 Articles